Impact of Vaccine Funding by the National Health Insurance on Vaccination Coverage Among Patients Targeted by Current Vaccination Recommendations and Followed in Outpatient Consultations

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

The objective of our study is to evaluate the impact of vaccine funding for patients seen in outpatient consultations within four healthcare institutions in the Ile-de-France region in France, made possible through the establishment of a tripartite agreement between the hospital group, the Île-de-France Regional Health Agency (ARS IDF), and the Primary Health Insurance Fund (CPAM).

Eligibility criteria

Qualifiers

Individuals aged 18 years or older,

Individuals followed in outpatient consultations within a department and healthcare institution participating in the project;

Individuals eligible for pneumococcal vaccination against according to current French recommendations,

Individuals meeting the eligibility conditions and receiving care under long-term illness coverage (ALD) or benefiting from complementary universal health coverage (C2S) or state medical aid (AME).

Disqualifiers

Individuals seen in settings other than outpatient consultations (day hospital, week hospital, conventional hospitalization, International Vaccination Center).

Trial design

Treatments tested in this trial

  • Questionnaires for patients
  • Questionnaires for healthcare providers

Treatment groups

2,920 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Assistance Publique - Hôpitaux de Paris

Lead sponsor

Agence régionale de santé Ile de France

Collaborator

Institut de Recherche en Santé Publique, France

Collaborator

URC-CIC Paris Descartes Necker Cochin

Collaborator